Angiotensin III (human, mouse): Mechanism, Evidence & Applications in RAAS Research

Executive Summary. Angiotensin III (human, mouse) (CAS: 13602-53-4) is a biologically active hexapeptide critical for cardiovascular and neuroendocrine research [APExBIO]. It mediates approximately 40% of the pressor response of angiotensin II and fully retains its aldosterone-stimulating capacity in vitro and in vivo [Oliveira et al., 2025]. Angiotensin III selectively interacts with both AT1 and AT2 receptor subtypes, with relative specificity for AT2, influencing blood pressure and endocrine signaling. The peptide’s molecular properties, solubility, and stability make it a preferred tool for modeling RAAS function and receptor pharmacodynamics. Recent studies also indicate angiotensin peptides may modulate host-pathogen interactions, highlighting translational relevance in disease modeling [Oliveira et al., 2025].

Biological Rationale

Angiotensin III (sequence: Arg-Val-Tyr-Ile-His-Pro-Phe) is produced by N-terminal cleavage of angiotensin II via aminopeptidase A activity in erythrocytes and tissues [Oliveira et al., 2025]. It is a functional component of the renin-angiotensin-aldosterone system (RAAS), a regulatory axis essential for blood pressure, fluid balance, and electrolyte homeostasis [Oliveira et al., 2025]. Angiotensin III maintains the ability to induce aldosterone secretion and suppress renin release, paralleling angiotensin II, but with distinctive receptor selectivity and pressor potency. The peptide is highly conserved across human and mouse models, facilitating translational research. Its molecular weight is 931.09 Da, with the chemical formula C₄₆H₆₆N₁₂O₉. Solubility is ≥23.2 mg/mL in water, ≥43.8 mg/mL in ethanol, and ≥93.1 mg/mL in DMSO. For stability, storage desiccated at -20°C is recommended; long-term solution storage is not advised [APExBIO].

Mechanism of Action of Angiotensin III (human, mouse)

Angiotensin III exerts its biological activity primarily via binding to AT1 and AT2 G protein-coupled receptors (GPCRs). The peptide demonstrates relative specificity for AT2, which is associated with vasodilatory, anti-fibrotic, and anti-inflammatory effects [Oliveira et al., 2025]. AT1 receptor activation by angiotensin III leads to aldosterone release, vasoconstriction, and blood pressure elevation. In rodent brain models, exogenous angiotensin III elicits both pressor and dipsogenic (thirst-inducing) responses. The peptide can suppress renin secretion, thus providing negative feedback within the RAAS. Molecularly, the presence of Arg at the N-terminus and Phe at the C-terminus is required for activity, and modifications (e.g., phosphorylation of Tyr⁴) alter receptor interaction and downstream signaling [Oliveira et al., 2025]. Angiotensin III is also implicated in modulating host-pathogen interactions through enhancement of viral spike protein-receptor binding in experimental models [Oliveira et al., 2025].

Evidence & Benchmarks

• Angiotensin III mediates ~40% of the vasopressor activity of angiotensin II in vivo (Oliveira et al., 2025, https://doi.org/10.3390/ijms26136067).
• It retains full aldosterone-stimulating effect in adrenal cortex assays (Oliveira et al., 2025, https://doi.org/10.3390/ijms26136067).
• Sequence: Arg-Val-Tyr-Ile-His-Pro-Phe; molecular weight 931.09 Da; chemical formula C₄₆H₆₆N₁₂O₉ (APExBIO, https://www.apexbt.com/angiotensin-iii-human-mouse.html).
• Solubility: ≥23.2 mg/mL (water), ≥43.8 mg/mL (ethanol), ≥93.1 mg/mL (DMSO) at room temperature (APExBIO, https://www.apexbt.com/angiotensin-iii-human-mouse.html).
• Angiotensin III binds both AT1 and AT2 receptors, modulating blood pressure and RAAS signaling (Oliveira et al., 2025, https://doi.org/10.3390/ijms26136067).
• Experimental studies show suppression of renin and induction of aldosterone secretion in both human and mouse tissues (Oliveira et al., 2025, https://doi.org/10.3390/ijms26136067).
• High-purity peptide available from APExBIO as product A1043 (https://www.apexbt.com/angiotensin-iii-human-mouse.html).

This article extends earlier mechanistic summaries by providing updated quantitative benchmarks and integrating recent findings on receptor interaction and translational disease modeling.

For more detailed molecular benchmarks, see this comparative analysis, which our article updates by including recent evidence on viral pathogenesis modulation.

Applications, Limits & Misconceptions

Angiotensin III is widely used in cardiovascular research to model pressor responses, receptor signaling, and endocrine feedback loops. It is also applied in neuroendocrine studies for its dipsogenic and central pressor effects in rodent models. The peptide is suitable for in vitro receptor pharmacology, in vivo hemodynamics, and disease modeling, including hypertension and aldosterone regulation. Emerging evidence suggests utility in modeling host-virus interactions due to its influence on spike protein-receptor binding [Oliveira et al., 2025]. However, it should not be used for chronic solution storage due to stability concerns, and its activity profile differs from other RAAS peptides such as angiotensin II and IV, particularly regarding receptor selectivity and pressor potency.

Common Pitfalls or Misconceptions

• Angiotensin III does not fully substitute for angiotensin II in all experimental contexts; pressor activity is lower (~40%) and receptor selectivity differs.
• Long-term storage in solution leads to degradation and activity loss; use desiccated powder at -20°C for best results.
• It is not a direct substrate for ACE; it is generated by aminopeptidase A cleavage of angiotensin II.
• Angiotensin III's activity depends on tissue context and receptor expression; results may not generalize across species or cell types.
• Mislabeling sequence or using impure peptide can confound results; always verify supplier and batch purity (e.g., APExBIO A1043).

Workflow Integration & Parameters

For experimental use, dissolve Angiotensin III (human, mouse) in water, ethanol, or DMSO to the required working concentration, ensuring full dissolution at ≥23.2 mg/mL (water), ≥43.8 mg/mL (ethanol), or ≥93.1 mg/mL (DMSO) at room temperature. Prepare aliquots fresh prior to use to avoid degradation. Store bulk peptide desiccated at -20°C. Typical in vitro concentrations range from 10 nM to 1 μM, with in vivo dosages adjusted based on model organism and research aim. Assay design should consider receptor subtype selectivity; AT2-dominant tissues may show distinct responses compared to AT1-rich systems. For benchmarking, refer to additional application protocols, which this article clarifies by specifying solution stability and mechanistic nuances.

Conclusion & Outlook

Angiotensin III (human, mouse) is a robust, validated peptide for dissecting RAAS pathway dynamics, receptor pharmacology, and neuroendocrine signaling in both fundamental and translational research. Its distinct mechanistic profile and molecular properties, as provided by APExBIO’s A1043 product, make it a preferred tool for cardiovascular and disease modeling experiments. Ongoing research continues to clarify its roles in host-pathogen interactions and expanded disease contexts, reinforcing the value of standardized, high-purity peptide reagents.